HOUSTON, June 9, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology, will
present the results from its pivotal cellulite trial through a
virtual video presentation at the American Academy of Dermatology
(AAD) 2020 Virtual Meeting, being held June
12-14, 2020 online at aad.org. The AAD adopted this new
virtual format as a result of their annual conference being
cancelled due to the COVID-19 crisis.
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
Leading dermatologist, Dr. Elizabeth
Tanzi, will present the results of Soliton's pivotal
cellulite study to participants at the AAD 2020 Virtual Meeting on
June 12, 2020 at 3:00 pm EST. While only participants in the
conference will be able to view the presentation to the AAD, the
Company will post the trial results to its website concurrently
with the presentation and will issue a press release regarding the
results on June 15, 2020. Dr. Tanzi
is a member of Soliton's Scientific Advisory Board.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton has completed a clinical study using the RAP device to
improve the appearance of cellulite and is investigating potential
additional capabilities of the RAP technology in preclinical
testing, including the potential to assist existing fat reduction
technology in the reduction of fat. The device is currently
cleared in the United States only
for use in tattoo removal and is not yet cleared for use to address
cellulite.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which statements involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of the Soliton RAP
device to demonstrate safety and efficacy in the reduction of
cellulite and the ability for Soliton to receive FDA clearance for
this additional indication. These statements relate to future
events, future expectations, plans and prospects. Although Soliton
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, actual results or
outcomes may prove to be materially different from the expectations
expressed or implied by such forward-looking statements. Soliton
has attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' "would," ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
in our filings with the Securities and Exchange Commission ("SEC"),
including under the heading " Risk Factors" in the Form 10-K for
year ended December 31, 2019 filed
with the SEC and as updated in our Form 10-Q filings and in our
other filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-to-announce-results-of-pivotal-cellulite-clinical-trial-301072556.html
SOURCE Soliton, Inc.